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Summary This study was undertaken to elucidate the mechanism of cellular resistance to BMS-181174, a novel analogue of mitomycin C
(MMC), in a human bladder cancer cell line. The BMS-181174-resistant variant (J82/BMS) was established by repeated continuous
exposures of parental cells (J82) to increasing concentrations of BMS-181174 (9-40 nM) over a period of about 17 months. A 2.6-fold higher
concentration of BMS-181174 was required to kill 50% of J82/BMS cell line compared with J82. The J82/BMS cell line exhibited collateral
sensitivity to 5-fluorouracil (5-FU), but was significantly more cross-resistant to MMC, melphalan, taxol, doxorubicin and VP-16. NADPH
cytochrome P450 reductase and DT-diaphorase activities, which have been implicated in bioreductive activation of MMC, were significantly
lower in the J82/BMS cell line than in J82. The cytotoxicity of BMS-181174, however, was not affected in either cell line by pretreatment with
dicoumarol, which is an inhibitor of DT-diaphorase activity. These results argue against a role of DT-diaphorase in cellular bioactivation of
BMS-181174, a conclusion consistent with that of Rockwell et al (Biochem Pharmacol, 50: 1239-1243, 1995). BMS-181174-induced DNA
interstrand cross-link (DNA-ISC) frequency was markedly lower in J82/BMS cell line than in J82 at every drug concentration tested. The
results of the present study suggest that cellular resistance to BMS-181174 in J82/BMS cell line may be due to reduced DNA-ISC formation.
However, the mechanism of relatively lower BMS-181174 induced DNA-ISC formation in J82/BMS cell line than in parental cells remains to
be clarified.
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Mitomycin C (MMC), a bioreductive alkylating agent, has shown
activity against various solid tumours, including bladder carci-
noma (Crooke and Bradner, 1976). However, the clinical useful-
ness of MMC is often restricted by its dose-limiting toxicity
(Crooke and Bradner, 1976; Doll et al, 1985). The most common
side-effect of MMC is delayed cumulative myelosuppression.
Even with an intermittent dosing schedule, the haematological
toxicity of MMC remains dose limiting (Crooke and Bradner,
1976; Doll et al, 1985). This has led to the synthesis ofanalogues,
in an attempt to identify anti-cancer agents with fewer side-effects
and/or superior anti-tumour activity than MMC (Doyle and Vyas,
1990). BMS-181174 is one such MMC analogue (see Figure 1 for
structures of MMC and BMS-181174) that has shown promise
preclinically (Doyle and Vyas, 1990; Bradner et al, 1990; Dusre et
al, 1990; Xu and Singh, 1992; Rockwell et al, 1995), and is
currently in clinical trials as an anti-cancer agent (Verweij et al,
1993; Talbot et al, 1994).
Toxicological studies have revealed that BMS-181174 is rela-
tively less toxic than MMC (Bradner et al, 1990). Preclinical
studies, including those from our laboratory, have shown that
BMS-181174 is significantly more cytotoxic than MMC in vitro
against a variety oftumour cells (Dusre et al, 1990; Xu and Singh,
1992; Xu et al, 1994a; Rockwell et al, 1995). It is important to
point out, however, that BMS-181174 has not always exhibited
superior anti-tumour activity in vivo compared with MMC
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(Bradner et al, 1990; Rockwell and Kelley, 1996). For example,
Bradner et al (1990) have documented that, whereas BMS-181174
is relatively superior than MMC against B16 melanoma, the anti-
tumour activity of this analogue is equivalent to that of the parent
drug against P388 and L1210 leukaemia, and M109 lung carci-
noma (Bradner et al, 1990).
Evidence is mounting that the mechanism of action of BMS-
181174 may be different from that of MMC. For example,
Rockwell et al (1995) havereported that BMS-181174 is relatively
more cytotoxic in air than in hypoxia, in contrast to MMC, which
is more active againsthypoxic tumour cells (Kennedy et al, 1980).
Likewise, He et al (1994) have shown that BMS-181174, but not
MMC, can be activated non-enzymatically in cell-free systems to
DNA-alkylating species by thiols such as glutathione (GSH). We
have shown previously that tumour cell sensitivity to MMC, but
not BMS-181174, is potentiated by ethacrynic acid, an inhibitor of
glutathione transferase (GST) activity (Xu and Singh, 1992).
Emergence of drug-resistant tumour cells is another limitation
in cancer chemotherapy for a number of anti-cancer agents,
including MMC. Clarification of the mechanisms of resistance to
chemotherapy drugs is, therefore, essential for devising strategies
to overcome the problem of drug resistance. Although several
different mechanisms have been proposed to account for tumour
cell resistance to MMC, including impaired drug activation
(Hoban et al, 1990; Pan et al, 1992; Xu et al, 1994b), reduced drug
accumulation (Dorr et al, 1987; Kobayashi et al, 1993; Shibata et
al, 1995), reduced oxygen radical formation (Dusre et al, 1990)
and increased GSH/GST- mediated drug inactivation (Xu and
Singh, 1992; Xu et al, 1994b), it remains to be seen whether or not
tumour cell resistance to BMS-181174 and MMC is manifested by
common mechanisms. In order to address this question, in the
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Figure 1 Structures of mitomycin C and BMS-181174
present study, we have established and characterized a BMS-
181174-resistant variant (J82/BMS) of a human bladder cancer
cell line (J82).
MATERIALS AND METHODS
Chemicals
BMS-181174, MMC, BMY 25282, VP-16 and 1,3-bis(2-
chloroethyl)- 1-nitrosourea (BCNU) were generous gifts from
Bristol-Myers Squibb (Evansville, IN, USA). 5-Fluorouracil
(5-FU), cisplatin, melphalan, 2,6-dichlorophenol indophenol
(DCPIP) and dicoumarol were obtained from Sigma (St Louis,
MO, USA). Taxol and doxorubicin were obtained from the
National Cancer Institute (Bethesda, MD, USA) and Farmitalia
Carlo Erba (Milan, Italy) respectively. ['4C]Thymidine (sp. act.,
56 mCi mmol-') was purchased from ICN (Irvine, CA, USA).
Drug solutions were prepared immediately before use. BMS-
181174 and BMY 25282 were dissolved in dimethyl sulphoxide
(DMSO), melphalan was solubilized in 0.1% hydrochloric acid,
and taxol and BCNU were dissolved in ethanol. Other drugs were
solubilized in phosphate-buffered saline (PBS). The final concen-
trations of DMSO and ethanol were < 0.025% and 0.1% respec-
tively. Neither of these solvents affected colony formation by the
cell lines examined in this study.
Cell culture and isolation of BMS-181174 resistant cell
line
Human bladder cancer cell line J82 was obtained from the ATCC
(Rockville, MD, USA). Monolayer cultures were maintained in
Eagle's minimum essential medium, supplemented with non-
essential amino acids, sodium pyruvate, 10% fetal bovine serum
and antibiotics. BMS-181174-resistant variant (J82/BMS) of J82
cells was established by repeated continuous exposures ofparental
cells to increasing concentrations of BMS-181174 (9-40 nM) in
vitro over aperiod ofabout 17 months. Cells were exposed to each
drug concentration for three passages and cultured in drug-free
medium for one passage before exposing to a higher BMS-181174
concentration. The J82/BMS cell line was maintained in drug-free
medium for 1 month before its characterization. The J82/BMS
cell line has been maintained in drug-free medium for more than
3 months without loss ofresistance to BMS-181174.
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Figure 2 Survival of J82 (0) and J82/BMS (@) cell lines, following 1 h
exposure to various concentrations of BMS-181174. Points represent mean
± s.d. of three independent experiments, except for survival of J82 cell line at
0.36 [M BMS-181174 concentration, where n = 2
Colony formation assay
The sensitivities of J82 and J82/BMS cells to various anti-cancer
drugs, including BMS-181174, were examined by colony forma-
tion assay. Briefly, 2 x 103 cells were plated in 25-cm2 flasks and
allowed to attach. Cells were exposed to different concentrations
of the desired drug for 1 h at 37°C, washed twice with PBS and
incubated in fresh drug-free complete medium. The flasks were
incubated for 7-8 days at 37°C in an atmosphere of 95% air and
5% carbon dioxide. Colonies were fixed and stained with 10%
buffered formalin containing 0.25% methylene blue and counted
under an inverted microscope. Colonies containing more than 50
cells were counted as survivors. The IC50 value (drug concentra-
tion producing 50% cell kill) was determined from a plot of per
cent cell survival vs drug concentration. In some experiments the
cells were first exposed to 100 gM dicoumarol for 15 min and then
treated with different concentrations ofBMS-181174 for 1 h in the
presence ofdicoumarol. Subsequently, the colony formation assay
was performed as described above.
Determination of cell cycle distribution
Approximately 106 cells, growing in log phase, were washed three
times with PBS, stained with propidium iodide and analysed by
using a Coulter dual-beam laser flow cytometer.
Enzyme assays
NADPH cytochrome P450 reductase and DT-diaphorase activities
were determined by the procedures described by Hrycay et al
(1975) andErmster(1967) respectively. DT-diaphorase activity was
measured by using DCPIP as a substrate. Protein and GSH levels
were determined by the methods of Bradford (1976) and Beutler
(1984) respectively. GST activity towards 1-chloro-2,4-dinitro-
benzene was determined by the method ofHabig et al (1974).
100
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Table 1 Characteristics of J82 and J82/BMS cell lines
J82 J82/BMS
Cell diameter (gim) 16 ± 3 (9)a 19 ± 4 (12)
Doubling time (h) 28 ± 3 (4) 32 ± 5 (3)
Plating efficiency (%) 32 ± 5 (3) 29 ± 2 (3)
Cell cycle distribution (%)
GoG1 42 ± 3 (3) 43 ± 2 (3)
S 43 ± 1 (3) 39 ± 2 (3)
G2M 15 ± 2 (3) 18 ± 2 (3)
aValues are mean ± s.d. of determinations indicated in the parentheses.
Alkaline elution assay
Approximately 2 x 106 cells were plated in 175-cm2 flasks and
labelled with 0.05 ,Ci ml-' ['4C]thymidine for 48 h at 370C.
Subsequently, the cells were trypsinized and 106 cells were
reseeded in 75-cm2 flasks. The radioactivity was chased by a 24-h
incubation in fresh medium containing 10 gm non-radioactive
thymidine. The labelled cells were exposed to the desired concen-
tration of BMS-181174 for 1 h at 37°C. The cells were washed
with PBS, trypsinized and aliquots containing approximately 106
cells were irradiated with 15 Gy ofgamma-radiation on ice. DNA
interstrand cross-link (DNA-ISC) formation was determined by
using the alkaline elution technique (Kohn et al, 1981). DNA-ISC
frequency was calculated by using the equation:
DNA-ISC (Gy eq.) = t[(l-R0)/(l-R1)]1/2-l } X 15,
where Ro and R, are the fractions of DNA retained on the filter
from control and BMS-181174 treated cells respectively.
RESULTS AND DISCUSSION
Survival curves forJ82 andJ82/BMS cell lines, following 1 h expo-
sure to BMS-181174, are illustrated in Figure 2. The IC50 values for
BMS-181174 in J82 and J82/BMS cells lines were 0.14 ± 0.04 and
0.37 + 0.03 gM respectively, indicating that an approximately 2.6-
fold higher concentration ofBMS-181174 was required to kill 50%
ofJ82/BMS cells than to kill 50% ofJ82 cells.
Table 1 summarizes the characteristics ofJ82 and J82/BMS cell
lines. The cell diameter, cell doubling time, plating efficiencies
and cell cycle distribution for J82 and J82/BMS cell lines were
similar.
Figure 3 shows the survival of J82 and J82/BMS cell lines
exposed to various concentrations of MMC and BMY 25282,
another analogue of MMC. The IC50 values for MMC in J82 and
J82/BMS cells, respectively, were about 0.35 ± 0.06 and
2.0 ± 0.2gM. TheIC50 values for BMY 25282 in J82 andJ82/BMS
cell lines were about 0.025 ± 0.005 and 0.09 ± 0.01 gM respec-
tively. These results indicate that the J82/BMS cell line is approxi-
mately 5.7- and 3.6-fold more cross-resistant to MMC and BMY
25282, respectively, than J82 cells.
Table 2 summarizes sensitivities ofJ82 and J82/BMS cell lines
to a number of other anti-cancer drugs. The drug sensitivity
profiles of a sixfold MMC-resistant variant of J82 cells (J82/
MMC; Xu et al, 1994b) and a 2.2-fold BMS-181174 resistant
subline of SCaBER cells (SCaBER/R; Singh et al, 1995) are also
shown in Table 2. Despite a similar level of resistance to BMS-
181174 in J82/BMS and SCaBER/R cells, the drug sensitivity
-
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Figure 3 Sensitivities of J82 (0) and J82/BMS (-) cell lines to mitomycin C
and BMY 25282. Points represent mean ± s.d. of three independent
experiments, except for survival of J82/BMS at 0.75 gM MMC concentration,
where n = 1
profiles ofthese cells were different. For example, whereas sensi-
tivities of J82 and J82/BMS cells to BCNU were similar (present
study), the SCaBERIR cell line was found to be 2.6-fold more
cross-resistant to this anti-cancer agent than SCaBER (Singh
et al, 1995). Another striking difference between J82/BMS and
SCaBER/R cells was about sixfold cross-resistance of J82/BMS
cells to melphalan compared with J82 (Table 2). In contrast, the
SCaBER/R cell line is not cross-resistant to melphalan (Singh et
al, 1995). Furthermore, the J82/BMS cell line, but not SCaBERIR,
exhibited a significant level ofcollateral sensitivity to 5-FU (Table
2, and Singh et al, 1995). The drug sensitivity profile ofJ82/BMS
cells was also different from that ofMMC-resistant variant ofJ82
cells (Xu et al, 1994b). Most noticeably, whereas J82/BMS cell
line displayed a 16-fold cross-resistance to taxol compared with
J82 (Table 2), the J82/MMC subline is collaterally sensitive to this
drug (Xu et al, 1994b).
Impaired drug activation, because ofdown-regulation of one or
more ofMMC bioactivation enzymes, has been proposed to be an
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Table 2 Sensitivities of J82 and J82/BMS cells to various anti-cancer drugs
Drug IC50 (M) Resistance indexa
J82 J82/BMS J82/BMS J82/MMC SCaBER/R
(present study) (Xu et al, 1994b) (Singh et al, 1995)
Mitomycin C 0.35 ± 0.06b 2 ± 0.2c 5.7 6.0 1.6
BMY 25282 0.025 ± 0.005 0.09 + 0.01C 3.6 3.0 2.0
Cisplatin 7±2 9+ 1 1.3 2.0 1.2
BCNU 13 ± 1 17 ± 3 1.3 1.0 2.6
Melphalan 5 ± 1 29 ± 7c 5.8 2.0 1.0
5-FU 457 ± 102 244± 74c 0.5 0.7 1.0
Taxol 0.25 + 0.03 4 ± 0.8c 16.0 0.36 NDd
Doxorubicin 0.5±0.03 1 ±0.1c 2.0 1.0 0.9
VP-16 6 ± 0.7 9± 1c 1.5 0.7 1.2
aResistance index, IC50 in J82/BMS cell line/IC50 in parental cells. bValues are mean ± s.d. of three or more independent experiments. cSignificantly
different from J82 by Student's t-test, P < 0.05. dNot determined.
Table 3 Glutathione levels, and NADPH cytochrome P450 reductase,
DT-diaphorase and glutathione transferase activities in J82 and J82/BMS
cell lines
J82 J82/BMS
NADPH cytochrome P450
reductase (nmol min-' mg-') 18 ± 2 (3)a 8 ± 0.5b (3)
DT-diaphorase (,umol min-1 mg-') 10 ± 3 (3) 5± 0.1b (3)
Glutathione content (nmol mg-') 135 ± 15 (5) 146 ± 17 (5)
Glutathione transferase (nmol min-' mg-') 125 ± 13 (3) 62 ± 6b (3)
aValues represent mean + s.d. of determinations indicated in the parentheses.
bSignificantly different from J82 by Student's t-test, P< 0.05.
important mechanism oftumour cell resistance to MMC (Hoban et
al, 1990; Pan et al, 1992; Xu et al, 1994b; Singh et al, 1996).
Several different enzymes have been shown to bioactivate MMC,
including NADPH cytochrome P450 reductase, DT-diaphorase,
xanthine oxidase, xanthine dehydrogenase and cytochrome b5
reductase (Rockwell et al, 1993). As shown in Table 3, NADPH
cytochrome P450 reductase and DT-diaphorase activities were
significantly lower (50-56%) in J82/BMS cells than in J82. As
xanthine oxidase and xanthine dehydrogenase activities are not
detectable in J82 cells (Xu et al, 1994b), these enzyme assays were
not performed in the present study.
To examine further the role of DT-diaphorase in BMS-181174
resistance ofJ82/BMS cell line, the effect of dicoumarol on cyto-
toxicity of BMS-181174 was investigated. The cytotoxicity
of BMS-181174 was not affected in either J82 or J82/BMS cells
by pretreatment with dicoumarol (data not shown), which is
an inhibitor of DT-diaphorase and cytochrome b5 reductase
(Rockwell et al, 1993). On the contrary, we have shown previously
that a similar treatment with dicoumarol significantly reduces the
cytotoxicity of MMC in both J82 and J82/MMC cells (Xu et al,
1994b). Rockwell et al (1995), using a mouse mammary tumour
cell line (EMT6), have also reported that the cytotoxicity of
BMS-181174 is not affected by dicoumarol pretreatment. Taken
together, these results argue against a role of DT-diaphorase or b5
reductase in cellular bioactivation of BMS-181174. Although the
catalytic efficiency of NADPH cytochrome P450 reductase in
bioactivation of BMS-181174 has not been determined, certain
observations argue against a role ofthis enzyme in bioactivation of
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Figure 4 BMS-181174-induced DNA interstrand cross-link formation in
J82 and J82/BMS cell lines as a function of varying drug concentration.
Points represent mean ± s.d. of three or four independent experiments,
except for 0.54 gM BMS-181174 concentration in J82 cell line, where n = 2.
0, J82/BMS; 0, J82
BMS-181174 as well. For example, Rockwell et al (1995) have
shown that BMS-181174 is relatively more cytotoxic under
aerobic conditions than in hypoxia. If NADPH cytochrome P450
reductase were to play a role in bioactivation of BMS-181174, its
cytotoxicity must be greater in hypoxia than in air, as has been
shown for MMC (Kennedy et al, 1980).
Recent studies have shown that, in cell-free systems, BMS-
181174, but not MMC, can be chemically activated to DNA-
alkylating species by thiols such as GSH (He et al, 1994). In order
to determine if alterations in cellular GSH levels contributed to
BMS-181174 resistance in J82/BMS cells, levels ofthis thiol were
determined in J82 and J82/BMS cells (Table 3). The GSH levels
were found to be similarin J82 andJ82/BMS cells. Enhanced GST-
mediated drug inactivation has also been suggested to contribute to
MMC resistance in some tumour cells (Xu and Singh, 1992; Singh
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et al, 1996). This enzyme activity, however, was significantly lower
in the BMS-181174 resistant cell line than in J82 (Table 3). These
results suggest that cellular resistance to BMS-181174 in J82/BMS
cell line may be independent ofthe GSHIGST system.
Previous studies have suggested that DNA-ISC, but not strand
breaks, may be the critical lesions in cytotoxic activity of BMS-
181174 (Dusre et al, 1990; Rockwell et al, 1995). We, therefore,
examined the DNA-ISC formation in these cell lines by using the
alkaline elution technique. As shown in Figure 4, BMS-181174
induced DNA-ISC formation in both cell lines in adose-dependent
manner. However, BMS-181174-induced DNA-ISC frequency
was markedly lower in the J82/BMS cell line than in J82 at every
drug concentration tested.
The results of the present study show that repeated continuous
exposures of J82 cells to increasing concentrations of BMS-
181174 results in a 2.6-fold resistant cell line. Further exposures of
the J82/BMS cell line to 40 nM BMS-181174 have been ineffective
in inducing a higher level of drug resistance (Xia and Singh,
unpublished observation). Nonetheless, the level of resistance
observed in the present study may be clinically relevant, because a
higher degree of resistance is unlikely to be observed in patients.
Our results suggest that the frequency and/or degree of acquired
resistance may be lower for BMS-181174 than MMC. Additional
support for this notion derives from our earlier studies that show
that BMS-181174 is unable to induce a higher level ofdrug resis-
tance (i.e. > 2.5-fold) in another human bladder cancer cell line
(Singh et al, 1995).
Another interesting observation of the present study is the cross-
resistance ofJ82/BMS cells to BMY25282. BMY 25282 has alower
quinone reduction potential than MMC (Doyle and Vyas, 1990), and
thus is bioactivated relatively easily compared with MMC. As a
result, tumour cells that are resistant to MMC because of impaired
drug activation do not show cross-resistance to BMY 25282 (Willson
et al, 1985; Hoban et al, 1990). As NADPH cytochrome P450 reduc-
tase and DT-diaphorase activities are significantly lower in J82/BMS
cells than in J82, cross-resistance of J82/BMS to BMY 25282 is
rather intriguing. The mechanism of cross-resistance of J82/BMS
cells to BMY 25282, however, remains to be clarified.
In summary, the results ofthe present study suggest that cellular
resistance of J82/BMS cell line to BMS-181174 may be due to
reduced DNA-ISC formation. While the mechanism of reduced
DNA-ISC frequency inJ82/BMS cell line awaits further investiga-
tion, some explanations can be offered for this effect. One possi-
bility is that enhanced repair of BMS-181174-induced DNA
cross-links may be responsible for reduced DNA-ISC in the
J82/BMS cell line, which appears to be a frequent mechanism of
resistance to various anti-cancer drugs. Altematively, the possi-
bility that lower DNA-ISC formation in the J82/BMS cell line
results from reduced drug accumulation cannot be ruled out.
However, further studies are needed to explore these possibilities.
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